1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Follicular Thyroid Cancer - Pipeline Review, H1 2016

Follicular Thyroid Cancer - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 83 pages

Follicular Thyroid Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Follicular Thyroid Cancer - Pipeline Review, H1 2016’, provides an overview of the Follicular Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Follicular Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Follicular Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Follicular Thyroid Cancer
- The report reviews pipeline therapeutics for Follicular Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Follicular Thyroid Cancer therapeutics and enlists all their major and minor projects
- The report assesses Follicular Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Follicular Thyroid Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Follicular Thyroid Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Follicular Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Follicular Thyroid Cancer - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Follicular Thyroid Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Follicular Thyroid Cancer - Overview 7
Follicular Thyroid Cancer - Therapeutics under Development by Companies 8
Follicular Thyroid Cancer - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Follicular Thyroid Cancer - Products under Development by Companies 12
Follicular Thyroid Cancer - Companies Involved in Therapeutics Development 13
Exelixis, Inc. 13
Genzyme Corporation 14
Novartis AG 15
Pfizer Inc. 16
Follicular Thyroid Cancer - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
cabozantinib s-malate - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
dabrafenib mesylate - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
everolimus - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
pasireotide - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
sunitinib malate - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
tetraiodothyroacetic acid - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
vandetanib - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Follicular Thyroid Cancer - Recent Pipeline Updates 55
Follicular Thyroid Cancer - Dormant Projects 80
Follicular Thyroid Cancer - Product Development Milestones 81
Featured News and Press Releases 81
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables
Number of Products under Development for Follicular Thyroid Cancer, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Follicular Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2016 13
Follicular Thyroid Cancer - Pipeline by Genzyme Corporation, H1 2016 14
Follicular Thyroid Cancer - Pipeline by Novartis AG, H1 2016 15
Follicular Thyroid Cancer - Pipeline by Pfizer Inc., H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Stage and Target, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 21
Number of Products by Stage and Route of Administration, H1 2016 23
Number of Products by Stage and Molecule Type, H1 2016 25
Follicular Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2016 55
Follicular Thyroid Cancer - Dormant Projects, H1 2016 80

List of Figures
Number of Products under Development for Follicular Thyroid Cancer, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Top 10 Targets, H1 2016 18
Number of Products by Stage and Top 10 Targets, H1 2016 18
Number of Products by Top 10 Mechanism of Actions, H1 2016 20
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 20
Number of Products by Routes of Administration, H1 2016 22
Number of Products by Stage and Routes of Administration, H1 2016 22
Number of Products by Molecule Types, H1 2016 24
Number of Products by Stage and Molecule Types, H1 2016 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) ...

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H2 2016

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Aryl Hydrocarbon Receptor (Class E Basic Helix Loop ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.